Benjamin Küpper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin Küpper has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rolf Wichmann
Kernforschungsanlage Jülich, Institut für Biotechnologie, Postfach 1913, D‐5170 Jülich, West Germany
3 shared publications - Lars Matthias Blank
Institute of Applied Microbiology – iAMB, Aachen Biology and Biotechnology – ABBt, Worringer Weg 1, RWTH Aachen University, D-52074, Aachen, Germany
2 shared publications - Till Tiso
Institute of Applied Microbiology RWTH Aachen University Aachen Germany
2 shared publications A. Imhoff
TU Dortmund, Fakultät Bio- und Chemieingenieurwesen, Arbeitsgruppe Bioverfahrenstechnik, Emil-Figge-Straße 66, D-44227 Dortmund, Germany
1 shared publicationA. Mause
TU Dortmund, Fakultät Bio- und Chemieingenieurwesen, Arbeitsgruppe Bioverfahrenstechnik, Emil-Figge-Straße 66, D-44227 Dortmund, Germany
1 shared publicationAdam Imhoff
Technische Universität Dortmund, Arbeitsgruppe Bioverfahrenstechnik, Emil-Figge Straße 66, 44227 Dortmund, Germany
1 shared publication
Latest Publications
- 25 April 2013
- Published by Wiley in Chemie Ingenieur Technik
- Vol. 85 (6) , 834-840
Fermentative Production of Monorhamnolipids in Pilot Scale – Challenges in Scale‐Up
Die fermentative Herstellung von Biotensiden wird meist durch die exzessive Bildung von stabilem Schaum erschwert. Am Beispiel von Monorhamnolipiden werden Vorschläge sowohl zur stabilen Aufrechterhaltung von begasten und gerührten Fermentationen wie auch zur Isolierung dieser Biotenside im größeren Maßstab gegeben, da diese kommerziell nur in sehr kleinen Mengen erhältlich sind. Ein besonderer Fokus liegt dabei auf der Verwendung nachwachsender Rohstoffe.
- 25 April 2013
- Published by Wiley in Chemie Ingenieur Technik
- Vol. 85 (6) , 834-840
Fermentative Production of Monorhamnolipids in Pilot Scale – Challenges in Scale‐Up
Die fermentative Herstellung von Biotensiden wird meist durch die exzessive Bildung von stabilem Schaum erschwert. Am Beispiel von Monorhamnolipiden werden Vorschläge sowohl zur stabilen Aufrechterhaltung von begasten und gerührten Fermentationen wie auch zur Isolierung dieser Biotenside im größeren Maßstab gegeben, da diese kommerziell nur in sehr kleinen Mengen erhältlich sind. Ein besonderer Fokus liegt dabei auf der Verwendung nachwachsender Rohstoffe.
- Open Access
- 25 July 2012
- Published by Wiley in Chemie Ingenieur Technik
- Vol. 84 (8) , 1196-1197
Fermentative Herstellung und Aufarbeitung von Monorhamnolipiden
- 25 July 2012
- Published by Wiley in Chemie Ingenieur Technik
- Vol. 84 (8) , 1196-1197
Open AccessFermentative Herstellung und Aufarbeitung von Monorhamnolipiden
- Open Access
- 17 October 2011
- Published by Springer Nature in Microbial Cell Factories
- Vol. 10 (1) , 80
Growth independent rhamnolipid production from glucose using the non-pathogenic Pseudomonas putida KT2440
Background: Rhamnolipids are potent biosurfactants with high potential for industrial applications. However, rhamnolipids are currently produced with the opportunistic pathogen Pseudomonas aeruginosa during growth on hydrophobic substrates such as plant oils. The heterologous production of rhamnolipids entails two essential advantages: Disconnecting the rhamnolipid biosynthesis from the complex quorum sensing regulation and the opportunity of avoiding pathogenic production strains, in particular P. aeruginosa. In addition, separation of rhamnolipids from fatty acids is difficult and hence costly. Results: Here, the metabolic engineering of a rhamnolipid producing Pseudomonas putida KT2440, a strain certified as safety strain using glucose as carbon source to avoid cumbersome product purification, is reported. Notably, P. putida KT2440 features almost no changes in growth rate and lag-phase in the presence of high concentrations of rhamnolipids (> 90 g/L) in contrast to the industrially important bacteria Bacillus subtilis, Corynebacterium glutamicum, and Escherichia coli. P. putida KT2440 expressing the rhlAB-genes from P. aeruginosa PAO1 produces mono-rhamnolipids of P. aeruginosa PAO1 type (mainly C10:C10). The metabolic network was optimized in silico for rhamnolipid synthesis from glucose. In addition, a first genetic optimization, the removal of polyhydroxyalkanoate formation as competing pathway, was implemented. The final strain had production rates in the range of P. aeruginosa PAO1 at yields of about 0.15 g/gglucose corresponding to 32% of the theoretical optimum. What's more, rhamnolipid production was independent from biomass formation, a trait that can be exploited for high rhamnolipid production without high biomass formation. Conclusions: A functional alternative to the pathogenic rhamnolipid producer P. aeruginosa was constructed and characterized. P. putida KT24C1 pVLT31_rhlAB featured the highest yield and titer reported from heterologous rhamnolipid producers with glucose as carbon source. Notably, rhamnolipid production was uncoupled from biomass formation, which allows optimal distribution of resources towards rhamnolipid synthesis. The results are discussed in the context of rational strain engineering by using the concepts of synthetic biology like chassis cells and orthogonality, thereby avoiding the complex regulatory programs of rhamnolipid production existing in the natural producer P. aeruginosa.
- 17 October 2011
- Published by Springer Nature in Microbial Cell Factories
- Vol. 10 (1) , 80
Open AccessGrowth independent rhamnolipid production from glucose using the non-pathogenic Pseudomonas putida KT2440
Background: Rhamnolipids are potent biosurfactants with high potential for industrial applications. However, rhamnolipids are currently produced with the opportunistic pathogen Pseudomonas aeruginosa during growth on hydrophobic substrates such as plant oils. The heterologous production of rhamnolipids entails two essential advantages: Disconnecting the rhamnolipid biosynthesis from the complex quorum sensing regulation and the opportunity of avoiding pathogenic production strains, in particular P. aeruginosa. In addition, separation of rhamnolipids from fatty acids is difficult and hence costly. Results: Here, the metabolic engineering of a rhamnolipid producing Pseudomonas putida KT2440, a strain certified as safety strain using glucose as carbon source to avoid cumbersome product purification, is reported. Notably, P. putida KT2440 features almost no changes in growth rate and lag-phase in the presence of high concentrations of rhamnolipids (> 90 g/L) in contrast to the industrially important bacteria Bacillus subtilis, Corynebacterium glutamicum, and Escherichia coli. P. putida KT2440 expressing the rhlAB-genes from P. aeruginosa PAO1 produces mono-rhamnolipids of P. aeruginosa PAO1 type (mainly C10:C10). The metabolic network was optimized in silico for rhamnolipid synthesis from glucose. In addition, a first genetic optimization, the removal of polyhydroxyalkanoate formation as competing pathway, was implemented. The final strain had production rates in the range of P. aeruginosa PAO1 at yields of about 0.15 g/gglucose corresponding to 32% of the theoretical optimum. What's more, rhamnolipid production was independent from biomass formation, a trait that can be exploited for high rhamnolipid production without high biomass formation. Conclusions: A functional alternative to the pathogenic rhamnolipid producer P. aeruginosa was constructed and characterized. P. putida KT24C1 pVLT31_rhlAB featured the highest yield and titer reported from heterologous rhamnolipid producers with glucose as carbon source. Notably, rhamnolipid production was uncoupled from biomass formation, which allows optimal distribution of resources towards rhamnolipid synthesis. The results are discussed in the context of rational strain engineering by using the concepts of synthetic biology like chassis cells and orthogonality, thereby avoiding the complex regulatory programs of rhamnolipid production existing in the natural producer P. aeruginosa.